Anti-Helicobacter pylori therapy followed by celecoxib on progression of gastric precancerous lesions

被引:91
作者
Zhang, Li-Jing [2 ]
Wang, Shi-Yan [1 ]
Huo, Xiao-Hui [2 ]
Zhu, Zhen-Long [3 ]
Chu, Jian-Kun [2 ]
Ma, Jin-Cheng [2 ]
Cui, Dong-Sheng [4 ]
Gu, Ping [4 ]
Zhao, Zeng-Ren [5 ]
Wang, Ming-Wei [4 ]
Yu, Jun [1 ]
机构
[1] Chinese Univ Hong Kong, Prince Wales Hosp, Dept Med & Therapeut, Shatin, Hong Kong, Peoples R China
[2] Hebei Med Univ, Affiliated Hosp 1, Dept Gastroenterol, Shijiazhuang 050051, Hebei Province, Peoples R China
[3] Hebei Med Univ, Affiliated Hosp 1, Dept Pathol, Shijiazhuang 050051, Hebei Province, Peoples R China
[4] Hebei Med Univ, Affiliated Hosp 1, Dept Neurol, Shijiazhuang 050051, Hebei Province, Peoples R China
[5] Hebei Med Univ, Affiliated Hosp 1, Dept Surg, Shijiazhuang 050051, Hebei Province, Peoples R China
关键词
Apoptosis; Cyclooxygenase; 2; Gastric precancerous lesions; Helicobacter pylori; Microvessel density; Proliferation; ACTIVATED-RECEPTOR-GAMMA; NONSTEROIDAL ANTIINFLAMMATORY DRUGS; SELECTIVE CYCLOOXYGENASE-2 INHIBITOR; SUPPRESS ANGIOGENESIS; COX-2; INHIBITORS; EPITHELIAL-CELLS; CANCER PATIENTS; TUMOR-GROWTH; MOUSE MODEL; LUNG-TUMORS;
D O I
10.3748/wjg.15.2731
中图分类号
R57 [消化系及腹部疾病];
学科分类号
100201 [内科学];
摘要
AIM: To evaluate whether celecoxib, a selective cyclooxygenase 2 (COX-2) inhibitor, could reduce the severity of gastric precancerous lesions following Helicobacter pylori (H pylori) eradication. METHODS: H pylori-eradicated patients with gastric precancerous lesions randomly received either celecoxib (n = 30) or placebo (n = 30) for up to 3 mo. COX-2 expression and activity was determined by immunostaining and prostaglandin E-2(PGE(2)) assay, cell proliferation by Ki-67 immunostaining, apoptosis by TUNEL staining and angiogenesis by microvascular density (MVD) assay using CD31 staining. increased in gastric precancerous lesions (atrophy, intestinal metaplasia and dysplasia, respectively) compared with chronic gastritis, and was concomitant with an increase in cell proliferation and angiogenesis. A significant improvement in precancerous lesions was observed in patients who received celecoxib compared with those who received placebo (P < 0.001). Of these three changes, 84.6% of sites with dysplasia regressed in patients treated with celecoxib (P = 0.002) compared with 60% in the placebo group, suggesting that celecoxib was effective on the regression of dysplasia. COX-2 protein expression (P < 0.001) and COX-2 activity (P < 0.001) in the gastric tissues were consistently lower in celecoxib-treated patients compared with the placebo-treated subjects. Moreover, it was also shown that celecoxib suppressed cell proliferation (P < 0.01), induced cell apoptosis (P < 0.01) and inhibited angiogenesis with decreased MVD (P < 0.001). However, all of these effects were not seen in placebo-treated subjects. Furthermore, COX-2 inhibition resulted in the up-regulation of PPAR gamma expression, a protective molecule with anti-neoplastic effects. CONCLUSION: H pylori eradication therapy followed by celecoxib treatment improves gastric precancerous lesions by inhibiting COX-2 activity inducing apoptosis, and suppressing cell proliferation and angiogenesis. (C) 2009 The WJG Press and Baishideng. All rights reserved.
引用
收藏
页码:2731 / 2738
页数:8
相关论文
共 42 条
[1]
Superior effectiveness of ibuprofen compared with other NSAIDs for reducing the survival of human prostate cancer cells [J].
Andrews, J ;
Djakiew, D ;
Krygier, S ;
Andrews, P .
CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2002, 50 (04) :277-284
[2]
Chemoprevention of colorectal neoplasia: The potential for personalized medicine [J].
Arber, Nadir ;
Levin, Bernard .
GASTROENTEROLOGY, 2008, 134 (04) :1224-1237
[3]
What role does Helicobacter pylori play in gastric cancer? [J].
Asaka, M ;
Takeda, H ;
Sugiyama, T ;
Kato, M .
GASTROENTEROLOGY, 1997, 113 (06) :S56-S60
[4]
Classification and grading of gastritis - The updated Sydney System [J].
Dixon, MF ;
Genta, RM ;
Yardley, JH ;
Correa, P ;
Batts, KP ;
Dahms, BB ;
Filipe, MI ;
Haggitt, RC ;
Haot, J ;
Hui, PK ;
Lechago, J ;
Lewin, K ;
Offerhaus, JA ;
Price, AB ;
Riddell, RH ;
Sipponen, P ;
Solcia, E ;
Watanabe, H .
AMERICAN JOURNAL OF SURGICAL PATHOLOGY, 1996, 20 (10) :1161-1181
[5]
Celecoxib inhibits Cdx2 expression and prevents gastric cancer in Helicobacter pylori-infected Mongolian gerbils [J].
Futagami, Seiji ;
Suzuki, Kenji ;
Hiratsuka, Tetsuro ;
Shindo, Tomotaka ;
Hamamoto, Tatsuhiko ;
Tatsuguchi, Atsushi ;
Ueki, Nobue ;
Shinji, Yoko ;
Kusunoki, Masanori ;
Wada, Ken ;
Miyake, Kazumasa ;
Gudis, Katya ;
Tsukui, Taku ;
Sakamoto, Choitsu .
DIGESTION, 2006, 74 (3-4) :187-198
[6]
Cyclooxygenase-2 (COX-2)-independent anticarcinogenic effects of selective COX-2 inhibitors [J].
Groesch, Sabine ;
Maier, Thorsten Juergen ;
Schiffmann, Susanne ;
Geisslinger, Gerd .
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE, 2006, 98 (11) :736-747
[7]
Hahm KB, 2003, J BIOCHEM MOL BIOL, V36, P82
[8]
Peroxisome proliferator-activated receptor γ:: a novel target for cancer therapeutics? [J].
Han, ShouWei ;
Roman, Jesse .
ANTI-CANCER DRUGS, 2007, 18 (03) :237-244
[9]
Honjo S, 2004, ANTICANCER RES, V24, P1439
[10]
Chemoprevention of gastric cancer by celecoxib in rats [J].
Hu, PJ ;
Yu, J ;
Zeng, ZR ;
Leung, WK ;
Lin, HL ;
Tang, BD ;
Bai, AHC ;
Sung, JJY .
GUT, 2004, 53 (02) :195-200